{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:04:40Z","timestamp":1791590680456,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"am","delay-in-days":264,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08774"],"award-info":[{"award-number":["22K08774"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Kagaku Gijutsu Shinko Kiko","doi-asserted-by":"publisher","award":["25K12000"],"award-info":[{"award-number":["25K12000"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejso.2025.110149","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T11:44:14Z","timestamp":1747136654000},"page":"110149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of neoadjuvant gemcitabine plus cisplatin-based triplet regimens on biliary tract cancer with possible lymph node metastasis"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8828-1067","authenticated-orcid":false,"given":"Shogo","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-3800","authenticated-orcid":false,"given":"Daisaku","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Tomimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-1129","authenticated-orcid":false,"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.110149_bib1","series-title":"General rules for Clinical and pathological studies on cancer of the biliary tract: the 7th edition","year":"2021"},{"issue":"5","key":"10.1016\/j.ejso.2025.110149_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10372","key":"10.1016\/j.ejso.2025.110149_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejso.2025.110149_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107324","article-title":"Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: an exploratory subset analysis of JCOG1202","volume":"50","author":"Kobayashi","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"4 suppl","key":"10.1016\/j.ejso.2025.110149_bib5","doi-asserted-by":"crossref","first-page":"TPS621","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS621","article-title":"Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT)","volume":"41","author":"Nara","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110149_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"issue":"5","key":"10.1016\/j.ejso.2025.110149_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jso.21501","article-title":"Multidetector computed tomography for preoperative prediction of postsurgical prognosis of patients with extrahepatic biliary cancer","volume":"101","author":"Kobayashi","year":"2010","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.110149_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ejso.2016.12.008","article-title":"A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer","volume":"43","author":"Kobayashi","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.110149_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jso.21811","article-title":"Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer","volume":"103","author":"Kobayashi","year":"2011","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.110149_bib10","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1245\/s10434-021-10820-6","article-title":"Preoperative FDG-positive lymph nodes predict the postoperative prognosis in resectable biliary tract cancers","volume":"29","author":"Kubo","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110149_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"8","key":"10.1016\/j.ejso.2025.110149_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.ejso.2025.110149_bib13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"suppl 4","key":"10.1016\/j.ejso.2025.110149_bib14","article-title":"A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110149_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jso.21971","article-title":"Treatment of borderline cases for curative resection of biliary tract cancer","volume":"104","author":"Kobayashi","year":"2011","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110149_bib16","first-page":"521","article-title":"Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report","volume":"107","author":"Makuuchi","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2025.110149_bib17","first-page":"434","article-title":"Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization","volume":"21","author":"Nagino","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2025.110149_bib18","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours eighth ed.. Union for International Cancer Control."},{"key":"10.1016\/j.ejso.2025.110149_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2025.110149_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/jhbp.1186","article-title":"A nationwide certification system to increase the safety of highly advanced hepatobiliary-pancreatic surgery","volume":"30","author":"Otsubo","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"3","key":"10.1016\/j.ejso.2025.110149_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.surg.2014.09.022","article-title":"Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence","volume":"157","author":"Takahashi","year":"2015","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.ejso.2025.110149_bib22","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1245\/s10434-022-12759-8","article-title":"Prognostic impact of gastroduodenal artery involvement in cancer of the pancreatic head","volume":"30","author":"Kado","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110149_bib23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1007\/s00595-020-01992-x","article-title":"Clinical significance of preoperative CA19-9 and lymph node metastasis in intrahepatic cholangiocarcinoma","volume":"50","author":"Asaoka","year":"2020","journal-title":"Surg Today"},{"issue":"1","key":"10.1016\/j.ejso.2025.110149_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10620-013-2894-4","article-title":"Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors","volume":"59","author":"Marubashi","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.ejso.2025.110149_bib25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00423-020-01955-3","article-title":"Invasion category-oriented lymph node metastases of cholangiocarcinoma and the prognostic impact","volume":"405","author":"Kobayashi","year":"2020","journal-title":"Langenbecks Arch Surg"},{"issue":"2","key":"10.1016\/j.ejso.2025.110149_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijsu.2012.12.006","article-title":"Clinicopathological features of long-term survivors for advanced biliary tract cancer and impact of the number of lymph nodes involved","volume":"11","author":"Kobayashi","year":"2013","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.ejso.2025.110149_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ags3.12418","volume":"5","author":"Akita","year":"2020","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.ejso.2025.110149_bib28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12885-024-12225-6","article-title":"A phase II\/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study","volume":"24","author":"Nager","year":"2024","journal-title":"BMC Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325005773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325005773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T01:44:31Z","timestamp":1757036671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325005773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0748798325005773"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110149","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of neoadjuvant gemcitabine plus cisplatin-based triplet regimens on biliary tract cancer with possible lymph node metastasis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110149"}}